Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study

J. Barnes (Cambridge, United Kingdom), E. Harris (Cambridge, United Kingdom), L. Matos (Cambridge, United Kingdom), K. Harding (Cambridge, United Kingdom), M. Thillai (Cambridge, United Kingdom)

Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Session: News in treatment and diagnosis of idiopathic interstitial pneumonia
Session type: E-poster
Number: 467

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Barnes (Cambridge, United Kingdom), E. Harris (Cambridge, United Kingdom), L. Matos (Cambridge, United Kingdom), K. Harding (Cambridge, United Kingdom), M. Thillai (Cambridge, United Kingdom). Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study. 467

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?
Source: Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020
Year: 2021



Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Exacerbations, hospitalisations and mortality in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems
Year: 2017



Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012



Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries.
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016

Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis?  Real- world results from the EMPIRE registry.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017

Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019



Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Source: ERJ Open Res, 5 (3) 00170-2018; 10.1183/23120541.00170-2018
Year: 2019



Effect of delayed secondary care referral on morbidity and mortality in idiopathic pulmonary fibrosis patients treated with antifibrotics
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019


Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study
Source: Breathe, 15 (2) 144; 10.1183/20734735.0016-2019
Year: 2019



A registry of patients with idiopathic pulmonary fibrosis in Russia: 2-yr results and therapeutic modalities in real-life practice
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019


Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015



Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018


Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012


Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry
Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019
Year: 2020



Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013

PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015